Loading...
XSHG
603108
Market cap872mUSD
Oct 09, Last price  
9.97CNY
1D
3.21%
1Q
6.18%
Jan 2017
-41.28%
IPO
99.80%
Name

Shanghai Runda Medical Technology Co Ltd

Chart & performance

D1W1MN
XSHG:603108 chart
P/E
—
P/S
0.86
EPS
—
Div yield, %
0.31%
Shrs. gr., 5y
0.82%
Rev. gr., 5y
-0.26%
Revenues
6.98b
-16.05%
631,452,386772,338,8321,025,889,5251,358,503,3221,628,641,8682,164,688,8404,318,809,8405,964,339,2237,051,950,1827,069,156,2898,860,108,02610,494,418,6939,147,372,7198,311,780,3556,977,711,007
Net income
-548m
L
54,495,55558,794,70967,940,01575,162,10991,760,323116,427,776219,186,711261,953,799309,509,507329,981,169380,229,139417,746,459273,296,49855,280,612-548,393,978
CFO
692m
+7.01%
23,374,09338,700,97231,623,69036,114,224000538,902,960246,678,613323,441,186371,112,6900801,750,549646,947,379692,303,171
Dividend
Jul 18, 20250.03 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shanghai Runda Medical Technology Co., Ltd. delivers a comprehensive array of integrated medical laboratory solutions throughout China. The company's extensive offerings cover vital operational aspects for laboratories, including the provision of essential platforms, expert design and refurbishment services for facilities, the establishment of standardization protocols, and the implementation of advanced information management systems. Furthermore, Shanghai Runda supports healthcare professionals by providing medical solutions for critical diagnostic fields such as biochemistry, diabetes, Point-of-Care Testing (POCT), immunoassay analysis, and molecular biology. Alongside these, they also furnish professional technical assistance and efficient logistical services. Established in 1999, the firm is headquartered in Shanghai, China.

Key people

Shanglin Liao
Chief Financial Officer · since 2020
Zhenning Hu
Deputy General Manager, Director · since 2023
Mo Chen
Director · since 2023
Hui Liu
Vice Chairman of the Board, General Manager · since 2023
Xiaoyan Lu
Deputy General Manager, Staff Elected Director · since 2026
Shenjie Yao
Director · since 2023
Chengxu Zhang
Chairman of the Board, Secretary of the Board · since 2023
Bin Zhao
Director · since 2026
Hwang Tong Chan
Independent Director · since 2023
Independent Director · since 2026
Jingjing Wang
Independent Director · since 2023
Mingwei Zhu
Independent Director · since 2026
IPO date
May 27, 2015
Employees
Domiciled in
CN
Incorporated in
CN
Headquarters & legal address
上海市金山区卫昌路1018号1号楼201室
金山区, SH 100000
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT